Study S000238

Bioequivalence of Two Survodutide (BI 456906) Formulations Via Subcutaneous Administration After Multiple Doses (an Open-label, Randomised, Multiple-dose, Crossover Trial)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07407348
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 80
Start: 2026-03-11
Primary completion: 2027-01-26
Lead sponsor: Boehringer Ingelheim
Conditions: Healthy; Obesity; Overweight
Interventions: COMBINATION_PRODUCT:Formulation A; COMBINATION_PRODUCT:Formulation B6
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: REGISTRY:U1111-1323-8960

Registered primary outcomes

Area under the concentration-time curve of survodutide in plasma at steady state over a uniform dosing interval tau (AUC tau,ss) [Up to 239 days.]
Maximum measured concentration of survodutide in plasma at steady state over a uniform dosing interval tau (Cmax,ss) [Up to 239 days.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.